P8IP
NBIX icon

Pier 88 Investment Partners’s Neurocrine Biosciences NBIX Stock Holding History

Pier 88 Investment Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$438K Sell
2,600
-4,400
-63% -$653K 0.1% 60
2026
Q1 		$922K Sell
7,000
-560
-7% -$74.3K 0.24% 50
2025
Q4 		$1.07M Buy
7,560
+1,010
+15% +$146K 0.24% 50
2025
Q3 		$919K Buy
6,550
+1,680
+34% +$228K 0.17% 62
2025
Q2 		$612K Sell
4,870
-3,680
-43% -$422K 0.11% 78
2025
Q1 		$946K Buy
8,550
+3,860
+82% +$489K 0.18% 57
2024
Q4 		$640K Buy
4,690
+1,600
+52% +$198K 0.13% 65
2024
Q3 		$356K Sell
3,090
-460
-13% -$63.1K 0.08% 81
2024
Q2 		$489K Buy
3,550
+2,100
+145% +$288K 0.11% 78
2024
Q1 		$200K Buy
+1,450
New +$198K 0.05% 90

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pier 88 Investment Partners's NBIX Position: Q2 2026 in Review

Pier 88 Investment Partners reduced its Neurocrine Biosciences (NBIX) stake by 63% in Q2 2026, selling an estimated $653K and leaving 2,600 shares worth $438K. The position accounts for 0.1% of the portfolio, ranked #60.

Pier 88 Investment Partners first reported a position in NBIX in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.07M in Q4 2025. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Pier 88 Investment Partners held 2,600 shares of Neurocrine Biosciences worth $438K as of Q2 2026.
  • Pier 88 Investment Partners sold 4,400 Neurocrine Biosciences shares in Q2 2026, an estimated $653K.
  • Neurocrine Biosciences made up 0.1% of Pier 88 Investment Partners's portfolio in Q2 2026, its #60 holding.
  • Pier 88 Investment Partners first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 10 quarters since.
  • Pier 88 Investment Partners's Neurocrine Biosciences position peaked at $1.07M in Q4 2025.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Pier 88 Investment Partners's 13F filing for Q2 2026, filed 4 Aug 2026.